Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus

Abstract Venous tumour thrombus (VTT), where the primary tumour invades the renal vein and inferior vena cava, affects 10–15% of renal cell carcinoma (RCC) patients. Curative surgery for VTT is high-risk, but neoadjuvant therapy may improve outcomes. The NAXIVA trial demonstrated a 35% VTT response...

Full description

Bibliographic Details
Published in:	Nature Communications
Main Authors:	Rebecca Wray, Hania Paverd, Ines Machado, Johanna Barbieri, Farhana Easita, Abigail R. Edwards, Ferdia A. Gallagher, Iosif A. Mendichovszky, Thomas J. Mitchell, Maike de la Roche, Jacqueline D. Shields, Stephan Ursprung, Lauren Wallis, Anne Y. Warren, Sarah J. Welsh, Mireia Crispin-Ortuzar, Grant D. Stewart, James O. Jones, On behalf of the NAXIVA Study Group
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-04-01
Online Access:	https://doi.org/10.1038/s41467-025-58436-8

Similar Items

Radiology and multi-scale data integration for precision oncology
by: Hania Paverd, et al.
Published: (2024-07-01)

Therapeutic effects of axitinib, an anti-angiogenic tyrosine kinase inhibitor, on interstitial cystitis
by: Jung Hyun Shin, et al.
Published: (2023-05-01)

Anti-angiogenic and antioxidant effects of axitinib in human retinal endothelial cells: implications in diabetic retinopathy
by: Francesca Lazzara, et al.
Published: (2024-06-01)

Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects.
by: Sophie J Bakri, et al.
Published: (2024-01-01)

Epithelioid Angiomyolipoma with Tumor Thrombus into Inferior Vena Cava Presurgically Treated with Combination Therapy of Pembrolizumab and Axitinib: A Case Report
by: Kawasoe C, et al.
Published: (2023-10-01)

Pembrolizumab and axitinib induced pathological complete response in metastatic clear cell renal cell carcinoma with inferior vena cava thrombus: A case report
by: Ryan Wong, et al.
Published: (2025-01-01)

Efficacy and safety of neoadjuvant therapy with tislelizumab plus axitinib for nonmetastatic renal cell carcinoma with inferior vena cava tumor thrombus: a retrospective study
by: Zhongjie Zhao, et al.
Published: (2025-01-01)

Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study
by: Liangyou Gu, et al.
Published: (2024-10-01)

Unexpected skin lesions after axitinib treatment
by: Ali Murat Sedef, et al.
Published: (2017-07-01)

Phase Separation Investigation of Axitinib in Supersaturated Solution
by: Jie Xu, et al.
Published: (2024-11-01)

Solvates and Polymorphs of Axitinib: Characterization and Phase Transformation
by: Yinhu Pan, et al.
Published: (2024-10-01)

Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
by: Na Wei, et al.
Published: (2018-03-01)

Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo
by: Zhang BW, et al.
Published: (2022-06-01)

Axitinib in sequential therapy in metastatic renal cell carcinoma
by: Agata Kuchar, et al.
Published: (2015-05-01)

A Case Report with Severe Thrombocytopenia Induced by Axitinib
by: Ulkuhan I. Koksal, et al.
Published: (2020-01-01)

Exploring the multifaceted antitumor activity of axitinib in lung carcinoids
by: Monica Oldani, et al.
Published: (2024-07-01)

Variables Affecting the Preparation and Characterization of Axitinib as Oral Niosmoes
by: Ibtihal Abdulkadhim Dakhil, et al.
Published: (2024-09-01)

Axitinib in metastatic renal cell carcinoma: single center experience
by: Agnieszka Buraczewska, et al.
Published: (2017-01-01)

Losartan Alleviates the Side Effects and Maintains the Anticancer Activity of Axitinib
by: Ying Fu, et al.
Published: (2022-04-01)

Position statement on clinical evaluation of imaging AI
by: Cathal McCague, et al.
Published: (2023-07-01)

UPLC-MS/MS analysis of axitinib and pharmacokinetic application in beagle dogs
by: Hengyu Bi, et al.
Published: (2024-10-01)

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
by: Bellesoeur A, et al.
Published: (2017-09-01)

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.
by: Annkristin Heine, et al.
Published: (2015-01-01)

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
by: Masaki Murata, et al.
Published: (2019-04-01)

Preparation and Evaluation of Oral Capsule-Based Niosomes for the Anti- Cancer Drug Axitinib
by: ibtihal abdulkadhim, et al.
Published: (2025-09-01)

Different mechanisms of axitinib and diazepam antiseizure action in pentylenetetrazol-induced kindling model
by: Leonid S. Godlevsky, et al.
Published: (2025-12-01)

Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
by: Ibon Gurruchaga Sotés, et al.
Published: (2021-06-01)

Impaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell Carcinoma
by: Masashi Kimura, et al.
Published: (2019-01-01)

Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma.
by: Stephan Ursprung, et al.
Published: (2021-01-01)

Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma
by: Stephan Ursprung, et al.
Published: (2021-01-01)

Fabrication and appraisal of targeted axitinib loaded bilosomes for the enhanced breast and ovarian anticancer activity.
by: Randa Mohammed Zaki, et al.
Published: (2025-01-01)

Theoretical investigation of fullerene (C60) as nano carrier for anti-cancer drug Axitinib
by: Saied Jamaladdin Emamjome Koohbanani, et al.
Published: (2024-03-01)

A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib
by: Shoichi Kimura, et al.
Published: (2023-07-01)

Evaluation of β-Catenin Inhibition of Axitinib and Nitazoxanide in Human Monocyte-Derived Dendritic Cells
by: Waqas Azeem, et al.
Published: (2021-08-01)

Oxidative stress suppression contributes to antiseizure action of axitinib and rapamycin in pentylenetetrazol-induced kindling
by: O. B. Poshyvak, et al.
Published: (2021-04-01)

Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma
by: Fanny Méjean, et al.
Published: (2026-12-01)

Cardiac Fibroelastoma versus Thrombus: Echocardiographic Evidence Can Be Misleading
by: John P. O’Laughlin, et al.
Published: (2016-01-01)

Final Analysis of Post‐Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan
by: Norio Nonomura, et al.
Published: (2025-01-01)

Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report
by: Huimin Zhang, et al.
Published: (2024-02-01)

Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review
by: Kenta Takahashi, et al.
Published: (2024-03-01)